Outlook Therapeutics, Inc. (OTLK) stock
OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$0.41+0.05 (+13.12%)
Close on Nov 18, 2026Market cap $99.30MP/E –Yield –
Outlook Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Outlook Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$55.64M. For fiscal 2025 it was -$67.06M. The highest annual figure on record is -$29.64M in fiscal 2018.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | -$67.06M | – |
| FY2024 | Sep 30, 2024 | -$71.70M | – |
| FY2023 | Sep 30, 2023 | -$53.13M | – |
| FY2022 | Sep 30, 2022 | -$63.07M | – |
| FY2021 | Sep 30, 2021 | -$51.73M | – |
| FY2020 | Sep 30, 2020 | -$36.84M | – |
| FY2019 | Sep 30, 2019 | -$36.30M | – |
| FY2018 | Sep 30, 2018 | -$29.64M | – |
| FY2017 | Sep 30, 2017 | -$35.88M | – |
| FY2016 | Sep 30, 2016 | -$51.35M | – |
| FY2015 | Sep 30, 2015 | -$46.56M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jun 30, 2026 | -$10.81M | – |
| Q2 FY2026CQ1 2026 | Mar 31, 2026 | -$14.03M | – |
| Q1 FY2026CQ4 2025 | Dec 31, 2025 | -$13.48M | – |
| Q4 FY2025CQ3 2025 | Sep 30, 2025 | -$17.31M | – |
| Q3 FY2025CQ2 2025 | Jun 30, 2025 | -$15.75M | – |
| Q2 FY2025CQ1 2025 | Mar 31, 2025 | -$12.39M | – |
| Q1 FY2025CQ4 2024 | Dec 31, 2024 | -$21.61M | – |
| Q4 FY2024CQ3 2024 | Sep 30, 2024 | -$22.88M | – |
| Q3 FY2024CQ2 2024 | Jun 30, 2024 | -$19.56M | – |
| Q2 FY2024CQ1 2024 | Mar 31, 2024 | -$18.94M | – |
| Q1 FY2024CQ4 2023 | Dec 31, 2023 | -$10.32M | – |
| Q4 FY2023CQ3 2023 | Sep 30, 2023 | -$12.46M | – |
| Q3 FY2023CQ2 2023 | Jun 30, 2023 | -$18.14M | – |
| Q2 FY2023CQ1 2023 | Mar 31, 2023 | -$6.84M | – |
| Q1 FY2023CQ4 2022 | Dec 31, 2022 | -$15.69M | – |
| Q4 FY2022CQ3 2022 | Sep 30, 2022 | -$13.99M | – |
| Q1 FY2022CQ4 2021 | Dec 31, 2021 | -$13.15M | – |
| Q4 FY2021CQ3 2021 | Sep 30, 2021 | -$13.44M | – |
| Q1 FY2021CQ4 2020 | Dec 31, 2020 | -$14.19M | – |
| Q4 FY2020CQ3 2020 | Sep 30, 2020 | -$10.01M | – |
| Q3 FY2020CQ2 2020 | Jun 30, 2020 | -$11.88M | – |
| Q2 FY2020CQ1 2020 | Mar 31, 2020 | -$6.76M | – |
| Q1 FY2020CQ4 2019 | Dec 31, 2019 | -$8.18M | – |
| Q4 FY2019CQ3 2019 | Sep 30, 2019 | -$12.69M | – |
| Q3 FY2019CQ2 2019 | Jun 30, 2019 | -$5.64M | – |
| Q2 FY2019CQ1 2019 | Mar 31, 2019 | -$7.71M | – |
| Q1 FY2019CQ4 2018 | Dec 31, 2018 | -$10.26M | – |
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | -$12.41M | – |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | -$7.22M | – |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | -$6.83M | – |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | -$3.18M | – |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | -$2.91M | – |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | -$7.34M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | -$7.84M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | -$17.80M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | -$9.95M | – |
| Q3 FY2016CQ2 2016 | Jun 30, 2016 | -$22.03M | – |
| Q2 FY2016CQ1 2016 | Mar 31, 2016 | -$2.95M | – |
See a number that looks wrong?